ANI Pharmaceuticals Inc (ANIP) Stock Forecast & Price Target
ANI Pharmaceuticals Inc · NASDAQ
$70.72+0.49 (+0.70%)
15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering ANI Pharmaceuticals Inc, 4 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $90.00 to $121.00, so the covering firms are broadly aligned. The average target of $105.83 sits 50% above the current $70.72. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 2 over recent months. On the fundamentals, the Street sees revenue growth near 27% this year and 11% next, consensus EPS building from about $2.86 next quarter toward $10.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy467%
Hold233%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to ANI Pharmaceuticals Inc.
As of Sep, 2 of 4 firms rate ANIP a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ANIP EPS & revenue forecast
EPS · NEXT QUARTER
$2.86
Range $2.70 – $2.95 · 8 analysts · +23% YoY
Next period, 8 analysts expect ANI Pharmaceuticals Inc to earn $2.86 a share (range $2.70 – $2.95), versus $2.33 a year earlier. Full-year consensus is $9.28, growing to $10.44 the year after.
REVENUE · NEXT QUARTER
$319.4M
Range $311.6M – $324.6M · 8 analysts · +31% YoY
Revenue is expected to reach $319.4M (range $311.6M – $324.6M), +31.0% year-over-year. Full-year consensus is $1.1B, rising to $1.2B next year.
Top analysts covering ANI Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANIP.
#1
David Amsellem
Piper Sandler · Rank #107
Buy
$111.00+57.0% to target
Overall win rate
50%
+ Follow
#2
Oren Livnat
HC Wainwright & Co. · Rank #170
Buy
$94.00+32.9% to target
Overall win rate
54%
+ Follow
#3
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$121.00+71.1% to target
Overall win rate
42%
+ Follow
#4
Elliot Wilbur
Raymond James · Rank #284
Buy
$83.00+17.4% to target
Overall win rate
32%
+ Follow
#5
Vamil Divan
Guggenheim
Buy
$119.00+68.3% to target
Coverage
—
+ Follow
ANIP stock forecast FAQ
What is ANIP's average 12-month price target?+
The 6 analysts with a live target average $105.83 for ANI Pharmaceuticals Inc over the next 12 months, ranging from a $121.00 high to a $90.00 low.
Is ANIP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 4 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ANIP?+
The Street-high target is $121.00 (HC Wainwright & Co.), and the Street-low is $90.00 (Canaccord Genuity). The average of all 6 active targets is $105.83.
How many Wall Street analysts cover ANIP?+
6 analysts have an active rating on ANI Pharmaceuticals Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering ANIP?+
Among analysts who currently cover ANIP, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #107). Their current call is Buy with a $111.00 target.
What is ANI Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $2.86 per share (range $2.70 – $2.95) across 8 analysts. Full-year EPS is projected at $9.28, rising to $10.44 the following year.
How much revenue is ANI Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $319.4M (range $311.6M – $324.6M). Full-year revenue is projected at $1.1B, growing to $1.2B next year.
Have analysts been upgrading or downgrading ANIP lately?+
As of Sep, 2 of 4 firms rate ANIP a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANIP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
